Delving into the Latest Updates on Hapten Sciences, Inc. with Synapse

概览

关联

1

项与 Hapten Sciences, Inc. 相关的药物

PDC-APB

靶点-

作用机制

免疫调节剂

在研机构

University of Mississippi

原研机构

University of Mississippi

在研适应症

皮炎

非在研适应症

接触性皮炎

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

2

项与 Hapten Sciences, Inc. 相关的临床试验

NCT04853823 / Unknown status临床1期

A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure

This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.

开始日期2021-11-01

申办/合作机构

Hapten Sciences, Inc.

[+1]

NCT02700373 / Completed临床1期

A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers

This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.

开始日期2016-03-01

申办/合作机构

Hapten Sciences, Inc.

100 项与 Hapten Sciences, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Hapten Sciences, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Hapten Sciences, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Hapten Sciences, Inc. 相关的转化医学

登录后查看更多信息